Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma

References

• Colman RW, Clowes AW, Goldhaber SZ, Marder VJ, George JN. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2006:1–16.
   Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M, Simone GD, Ferguson TB, Flegal K et al. Heart Disease and Stroke Statistics – 2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21–e181.
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339–5356.
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820–829.
   PubMed Web of Science ®Google Scholar
• Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 2008;6:1736–1741.
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Watson CA, Xin B. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 2009;7:1313–1320.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807–815.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594–604.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877–2885.
   PubMed Web of Science ®Google Scholar
• Buller H, Deitchman D, Prins M, Segers A; Botticelli Investigators, Writing Committe. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313–1318.
   PubMed Web of Science ®Google Scholar
• Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980;255:274–283.
   PubMed Web of Science ®Google Scholar
• Nesheim ME, Kettner C, Shaw E, Mann KG. Cofactor dependence of factor Xa incorporation into the prothrombinase complex. J Biol Chem 1981;256:6537–6540.
   PubMed Web of Science ®Google Scholar
• Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34:39–57.
   PubMed Web of Science ®Google Scholar
• Zikria JC, Ansell J. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Curr Opin Hematol 2009;16:347–356.
   PubMed Web of Science ®Google Scholar
• Nilsson T, Sjöling-Ericksson A, Deinum J. The mechanism of binding of low-molecular weight active site inhibitors to α-thrombin. J Enzyme Inhibition 1988;13:11–29.
   Google Scholar
• Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504–1514.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 1997;36:12080–12086.
   PubMed Web of Science ®Google Scholar
• Christensen U, Müllertz S. Kinetic studies of the urokinase catalysed conversion of NH2-terminal lysine plasminogen to plasmin. Biochim Biophys Acta 1977;480:275–281.
   PubMed Web of Science ®Google Scholar
• Segel I. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York: John Wiley & Sons, Inc. 1993:100–178 and 931–940.
   Google Scholar
• Schoen P, Lindhout T. The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin. J Biol Chem 1987;262:11268–11274.
   PubMed Web of Science ®Google Scholar
• Cha S, Agarwal RP, Parks RE Jr. Tight-binding inhibitors-II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. Biochem Pharmacol 1975;24:2187–2197.
   PubMed Web of Science ®Google Scholar
• Morrison JF, Stone SR. Approaches to the study and analysis of the inhibition of enzymes by slow and tight-binding inhibitors. Comments Mol Cell Biophys 1985;2:347–368.
   Google Scholar
• Mann KG. Prothrombin. Methods Enzymol 1976;45:123–156.
   PubMedGoogle Scholar
• Hemker HC, Vermeer C, Govers-Riemslag J. Kinetic aspects of the interaction of blood clotting enzymes. VII. The relation between clotting time and prothrombin concentration. Thromb Haemost 1977;37:81–85.
   PubMed Web of Science ®Google Scholar
• Weber G. Van’t Hoff revisited: enthalpy of association of protein subunits. J Phys Chem 1995;99:1052–1059.
   Web of Science ®Google Scholar
• Rosing J, Zwaal RF, Tans G. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation. J Biol Chem 1986;261:4224–4228.
   PubMed Web of Science ®Google Scholar
• Qureshi SH, Yang L, Manithody C, Rezaie AR. Membrane-dependent interaction of factor Xa and prothrombin with factor Va in the prothrombinase complex. Biochemistry 2009;48:5034–5041.
   PubMed Web of Science ®Google Scholar
• Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001;97:2308–2313.
   PubMed Web of Science ®Google Scholar
• Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47:5481–5492.
   PubMed Web of Science ®Google Scholar
• Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002;100:148–152.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988;263:3823–3834.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem 1986;261:8977–8984.
   PubMed Web of Science ®Google Scholar
• Giesen PL, Willems GM, Hermens WT. Production of thrombin by the prothrombinase complex is regulated by membrane-mediated transport of prothrombin. J Biol Chem 1991;266:1379–1382.
   PubMed Web of Science ®Google Scholar